Objective To gain a deeper understanding of the hot topics and future prospects of
programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors …

Abstract Anti-PD-1/PD-L1 inhibitors provide a survival advantage over conventional
therapies for treatment of advanced or metastatic cancer. However, the factors determining …

Background To review and summarize all US Food and Drug Administration (FDA)
approvals of programmed death (PD)-1 and PD-ligand 1 blocking antibodies (collectively …

Background A high number of combinations of PD-1/PD-L1 inhibitors with other anti-cancer
therapies are in clinical development. The usefulness of phase II trials in evaluating their …

Background: Comprehensive evidence comparing treatment-related adverse events (trAEs)
among PD-1/PD-L1 inhibitors is unavailable. Methods: A systematic review and network …

Objectives To identify the cooperation of authors, countries, and institutions and explore the
hot topics and future prospects regarding programmed cell death protein 1 (PD-1) and …

Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …

Background Understanding the safety and adverse event profiles of PD-1/PD-L1 inhibitors is
important in guiding cancer immunotherapy. Consequently, we designed this meta-analysis …

Objective: to evaluate the risk of treatment-related adverse events of different severity and
different system with PD-1 or PD-L1 inhibitors. Methods: randomized controlled trials (RCTs) …

Background PD-1/PD-L1 inhibitors have been implicated as potentially effective anti-cancer
therapies. Some clinical randomized controlled trials (RCTs) have been completed for a …